However, choosing between Xenium, CosMx and GeoMx is not simply a question of resolution or plex. Each platform is designed with different biological questions, sample types and study endpoints in mind. Selecting the wrong approach can introduce unnecessary complexity, consume precious tissue, and generate large datasets that do not translate into actionable insight.
In this webinar, Propath explores how to select the right spatial transcriptomics approach, with a focus on study design, tissue quality, platform fit, a multidisciplinary team and the route from exploratory data to translational insight.
1. What is spatial transcriptomics and how is it used
Spatial transcriptomics enables researchers to answer key questions around tissue organisation, cell–cell interactions, and how disease or treatment response varies with spatial context. We will introduce how these approaches are being used across discovery, translational research and biomarker development.
2. Match the platform to the research question
Xenium, CosMx and GeoMx offer different strengths across discovery, hypothesis-led research and focused validation. We will discuss where each platform fits, what level of resolution it provides and which questions it is best placed to answer.
3. Understand when single-cell spatial resolution is needed
Single-cell resolution can provide valuable insight, but it is not necessary for every study. Learn when it adds meaningful biological value and when a regional or compartment-based approach may be more appropriate.
4. Protect precious tissue through better study preparation
Spatial studies often depend on limited FFPE tissue, including small clinical biopsies. Sample preparation is key; we will explain how section quality, tissue adhesion, RNA integrity and pre-run quality control influence the likelihood of study success.
5. Design the analysis before generating the data
Sample selection, experimental groups, time points and bioinformatics should be aligned with the intended development decision. Learn how to avoid generating complex or inappropriate data without a clear analytical route.
6. Plan the path from discovery to validation
Spatial transcriptomics is often the starting point rather than the final endpoint. See how RNA signatures can be prioritised and validated through IHC, multiplex immunofluorescence and other effector-level approaches.
Who should attend?
This webinar is for spatial biology teams, translational scientists, biomarker leads, clinical development teams, bioinformaticians, biotech executives and pharma decision-makers planning or evaluating spatial transcriptomics studies.
Why attend?
Because the platform with the highest resolution is not automatically the right platform for your study.
Join this Propath webinar to learn how to select the right spatial approach, reduce technical risk, protect valuable tissue and generate findings that can support biomarker and development decisions
Kelly Hunter is Chief Scientific Officer at Propath UK, where he leads the company’s scientific strategy and development of advanced spatial biology services across spatial proteomics, spatial transcriptomics, multiplex immunofluorescence and single-cell spatial analysis. With substantial experience in implementing and commercialising cutting-edge tissue profiling technologies, Kelly works closely with pharmaceutical and biotechnology partners to design translational research and biomarker strategies that generate meaningful, decision-ready data from limited clinical samples. His expertise spans complex assay development, custom high-plex panel design, spatial multiomics workflows and the integration of robust bioinformatics to translate rich tissue data into actionable biological insight. At Propath, Kelly helps clients apply responsive, GCP-compliant spatial biology solutions to support mechanism-of-action studies, biomarker discovery, clinical trial delivery and confident decision-making across the drug development pipeline.
.png)
Joana Campos is a Senior Study Director and Spatial Biology Team Lead at Propath UK. An experienced immunologist, Joana completed her PhD in Immunity and Infection at the University of Birmingham and subsequently performed doctoral research at the Institute of Inflammation and Ageing, publishing in autoimmunity, fibroblast subsets and spatial methods.
Dave Swatman leads Propath’s commercial operations and strategic partnerships. He has extensive experience supporting pharmaceutical and biotechnology companies through outsourced pathology and translational research services and has played a key role in the commercial launch of Propath’s spatial biology capabilities.
